Assertio Holdings Business Summary

Assertio Holdings, Inc. (ASRT) is a specialty pharmaceutical company that operates a commercial-stage business model centered on the acquisition and commercialization of branded prescription therapeutics. The company generates revenue primarily through net product sales within three core segments: Oncology, Neurology, and Pain Management. Its current portfolio is anchored by Rolvedon (eflapegrastim-xnst) for chemotherapy-induced neutropenia, the Indocin family of products, and Sympazan. Assertio utilizes a lean, omni-channel promotional strategy designed to maximize asset value through targeted digital and sales force engagement while maintaining a low-cost operational structure. Within the competitive landscape, Assertio rivals specialty firms such as Jazz Pharmaceuticals, Medexus Pharmaceuticals, and Pacira BioSciences. The company positions itself as a strategic aggregator in the small-cap pharmaceutical space, focusing on acquiring divested or undervalued assets with established clinical profiles to drive cash flow and shareholder value. Originally founded in 1995 as Depomed by John Shell, the company is currently led by Chief Executive Officer Mark L. Reisenauer, who assumed the role in October 2025 after serving as President of U.S. Commercial at Astellas Pharma. The leadership team includes President and COO Paul Schwichtenberg, promoted in November 2025, and Executive Vice President and CFO Ajay Patel, who has managed the company’s financial operations since 2023. The board is chaired by Heather L. Mason, an industry veteran with extensive experience at Abbott Laboratories. Assertio’s strategic direction is supported by a history of institutional backing from firms such as Deerfield Management and HBM Healthcare Investments. This leadership group is currently focused on the full integration of the Spectrum Pharmaceuticals acquisition and the stabilization of the Rolvedon commercial trajectory following a 1-for-15 reverse stock split executed in late 2025.